Guest blog: Patents in the biopesticide industry revealed

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Guest blog: Patents in the biopesticide industry revealed

Who is applying for patents in the biopesticide industry? Rubal Walia of INDUS TechInnovations explains

Although synthetic chemical fertilizers occupy a large share of pesticide market, biopesticides are gradually gaining significance. We have been looking at the patent landscape as well as the trends and patterns emerging in the Biopesticide industry.

We studied the patent filings in this technology area to understand the investments and patenting efforts being made. The infographic below outlines some interesting trends such as the pace of progress over the last decade, the geographical distribution of patents, patent transactions between different organisations and top patent asset holders.

The report displays a steady increase in published patents over the years, with 2012 revealing a sharp rise. Geographically, the US and China have dominated this area in patents and applications, followed by Europe. In addition, Monsanto, one of the pioneers in developing genetically modified seeds, leads the race as the top patent asset holder, with more than 1,400 patents. Pioneer, a Dupont company, is close behind with more than 1,000 patents.

The report also indicates that Monsanto is among the top acquirers of patents, buying patents from companies such as D&PL Technologies, Pharmacia, and Ecogen. Rivals Bayer and Gibraltar Business Capital have also acquired a large number of patents. You can see more information in the graphic.

Image The infographic was produced by Relecura, a patent and portfolio analysis platform developed by INDUS TechInnovations.

more from across site and SHARED ros bottom lb

More from across our site

The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Gift this article